Literature DB >> 2458948

Transcriptional and post-transcriptional regulation of c-myc, c-myb, and p53 during proliferation and differentiation of murine erythroleukemia cells treated with DFMO and DMSO.

S P Klinken1, K L Holmes, H C Morse, S S Thorgeirsson.   

Abstract

The proto-oncogenes myc, myb, and p53 produce nuclear proteins which have been implicated in the regulation of proliferation or differentiation in a number of systems. The expression of these proto-oncogenes was studied in murine erythroleukemia (MEL) cells during (i) normal replication, (ii) DMSO-induced differentiation and (iii), alpha-difluoromethylornithine (DFMO)-restricted cell division and differentiation. The RNA levels of c-myc, c-myb, and p53 were all elevated during normal cellular proliferation; only c-myc expression declined when the cells stopped dividing although the rate of transcription for the gene was unaltered. In contrast, treatment of the cells with DFMO resulted in gradual cessation of cell replication and a decrease in transcription of c-myc, c-myb and p53. When the MEL cells were induced to differentiate with dimethyl sulfoxide (DMSO), a transient reduction in c-myc and c-myb RNA levels occurred immediately prior to the G1 arrest with a concomitant decrease in transcriptional activity, while p53 mRNA production was elevated without an increase in transcription. Similar changes of the proto-oncogene levels were observed when the MEL cells were incubated with DFMO and then later induced with DMSO, a protocol which restricts differentiation of the MEL cells. From these experiments we conclude that (i) c-myc, c-myb, and p53 are regulated independently at both the transcriptional and post-transcriptional levels, (ii) DFMO inhibits MEL cell proliferation and expression of several genes, including c-myc, c-myb and p53, and (iii) DFMO suppresses terminal differentiation but is unable to alter proto-oncogene changes associated with the early stages of differentiation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458948     DOI: 10.1016/0014-4827(88)90390-4

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  cis-Acting Elements for Light Regulation of Pea Ferredoxin I Gene Expression Are Located within Transcribed Sequences.

Authors:  R. C. Elliott; L. F. Dickey; M. J. White; W. F. Thompson
Journal:  Plant Cell       Date:  1989-07       Impact factor: 11.277

2.  Alteration in p53 modulates glial proteins in human glial tumour cells.

Authors:  H S U; A Banaie; L Rigby; J Chen; H Meltzer
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

3.  Differential binding of nuclear factors to the intron 1 sequences containing the transcriptional pause site correlates with c-myb expression.

Authors:  C D Reddy; E P Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

4.  Prevention by alpha-difluoromethylornithine of skin carcinogenesis and immunosuppression induced by ultraviolet irradiation.

Authors:  H L Gensler
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

5.  Single-strand conformational polymorphism analysis of a common single nucleotide variation in WRAP53 gene, rs2287499, and evaluating its association in relation to breast cancer risk and prognosis among Iranian-Azeri population.

Authors:  Aida Sedaie Bonab; Nasser Pouladi; Mohammad Ali Hosseinpourfeizi; Reyhaneh Ravanbakhsh Gavgani; Roghayeh Dehghan; Parvin Azarfam; Vahid Montazeri; Ashraf Fakhrjou
Journal:  Med Oncol       Date:  2014-08-19       Impact factor: 3.064

6.  Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation.

Authors:  C M Cultraro; T Bino; S Segal
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

7.  MicroRNA-125b is a novel negative regulator of p53.

Authors:  Minh T N Le; Cathleen Teh; Ng Shyh-Chang; Huangming Xie; Beiyan Zhou; Vladimir Korzh; Harvey F Lodish; Bing Lim
Journal:  Genes Dev       Date:  2009-03-17       Impact factor: 11.361

8.  Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.

Authors:  Altaf Mohammed; Naveena B Janakiram; Venkateshwar Madka; Rebekah L Ritchie; Misty Brewer; Laura Biddick; Jagan Mohan R Patlolla; Michael Sadeghi; Stan Lightfoot; Vernon E Steele; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-09-23

9.  ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers.

Authors:  Meenu Madan; Arjun Patel; Kristen Skruber; Dirk Geerts; Deborah A Altomare; Otto Phanstiel Iv
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

10.  Low dose dimethyl sulfoxide driven gross molecular changes have the potential to interfere with various cellular processes.

Authors:  Sinem Tunçer; Rafig Gurbanov; Ilir Sheraj; Ege Solel; Okan Esenturk; Sreeparna Banerjee
Journal:  Sci Rep       Date:  2018-10-04       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.